Stada and Mylan targeting Bristol-Myers Squibb’s Upsa (€1bn)

Germany-based generics producer Stada is reportedly targeting French OTC manufacturer Upsa, owned by Bristol-Myers Squibb. The news has been reported by Reuters, according to which Mylan and France-based Pierre Fabre are targeting the company too. Upsa has 1,500 employees and last year generated revenues of €425m, with an €100m EBIT. It has potential to reach €1bn in value.

(Source: Reuters)